Preprint
Review

This version is not peer-reviewed.

Thymosin β4 and BPC-157 as Candidate Regenerative Peptide Therapies for Spinal Cord Injury: Mechanisms, Preclinical Evidence, and First Clinical Signals

Submitted:

13 November 2026

Posted:

16 November 2026

You are already at the latest version

Abstract
Spinal cord injury (SCI) remains without an approved pharmacological therapy capable of restoring lost neurological function, and recovery in motor-complete, sensory-incomplete (AIS B) patients is constrained by a limited spontaneous-conversion profile. Two regenerative peptides have assembled convergent preclinical rationales in SCI. Thymosin β4 (Tβ4), the principal G-actin-sequestering peptide of eukaryotic cells, promotes oligodendrogenesis, axonal remodeling, angiogenesis, and anti-inflammatory signalling, and has improved functional recovery in rodent SCI. The stable gastric pentadecapeptide BPC-157 acts chiefly through VEGFR2 upregulation and the Akt–eNOS nitric-oxide axis, and has produced consistent functional recovery in rat SCI models. This review synthesises the molecular pharmacology of both agents, the preclinical SCI literature, the limited human exposure data, and the safety and regulatory context, including the important distinction between full-length Tβ4 and the synthetic fragment TB-500. It then examines the first clinical signal: a 6-month open-label controlled pilot in subacute AIS-B thoracic SCI in which weekly subcutaneous Tβ4 plus BPC-157, added to intensive rehabilitation, was associated with larger motor, sensory, trunk, and autonomic gains than rehabilitation alone, with only mild adverse effects. The evidence base remains preclinical-first and hypothesis-generating; the design requirements for a confirmatory trial are outlined. Neither peptide is approved for SCI, and both are subject to significant regulatory restrictions.
Keywords: 
;  ;  ;  ;  ;  ;  ;  

1. Introduction

Traumatic spinal cord injury (SCI) affects an estimated 0.9 to 1.3 million people worldwide each year, and thoracic-level injuries graded AIS B—motor-complete but sensory-incomplete, with sacral sparing—occupy a therapeutically pivotal position. Sacral sensory preservation signals anatomical continuity across the lesion, yet no voluntary motor output reaches the lower limbs [1,2]. Natural-history data indicate that although roughly 65–75% of AIS B and C patients convert upward by one grade or more, functional ambulation remains uncommon, and most conversion is concentrated in the first 6 to 12 months after injury [3,4,5]. No approved drug acts on the biological substrate of the lesion itself. Intensive, task-specific rehabilitation remains the only intervention with consistent human evidence, exploiting spinal sensorimotor circuitry capable of generating stepping when appropriately driven by afferent input [6,7].
Two regenerative peptides have independently assembled preclinical rationales that map onto the core pathological processes of subacute SCI: persistent perilesional ischaemia, chronic microglial activation, immature and leaky neovasculature, and a demyelinated but structurally spared axonal rim. Thymosin β4 (Tβ4) and the stable gastric pentadecapeptide BPC-157 have each improved locomotor outcomes in rodent SCI when administered individually [8,9,10], and their mechanisms are mechanistically non-redundant and plausibly complementary. Until recently, neither had been studied in human SCI. This narrative review (i) synthesises the molecular pharmacology of both agents, (ii) reviews the preclinical SCI evidence, (iii) clarifies the frequently conflated distinction between full-length Tβ4 and the synthetic fragment TB-500, (iv) summarises the first human clinical signal in SCI—a 6-month open-label controlled pilot of the combination in AIS B thoracic injury [11]—and (v) outlines the safety, regulatory, and trial-design considerations that will determine whether these peptides progress to confirmatory evaluation.

2. Thymosin β4

2.1. Molecular Pharmacology

Tβ4 is a highly conserved 43-amino-acid peptide and the dominant G-actin–sequestering molecule in eukaryotic cells; it caps both ends of the actin monomer, severs filaments, and acts as a leaky barbed-end cap [12,13]. This cytoskeletal function is directly relevant to axonal growth-cone dynamics: Tβ4 promotes Mauthner axon regeneration in zebrafish by facilitating actin polymerisation through G-actin binding, and its knockout impairs regeneration [14]. Beyond actin regulation, Tβ4 is pleiotropically regenerative, driving cell migration, angiogenesis, extracellular-matrix remodelling, and anti-inflammatory signalling across a wide range of tissue-injury models [15,16].

2.2. Neurorestorative Mechanisms

The neurorestorative profile of Tβ4 rests on four pillars. First, oligodendrogenesis: Tβ4 stimulates proliferation and maturation of oligodendrocyte progenitor cells into myelinating oligodendrocytes, mediated by p38 MAPK activation with parallel inactivation of ERK1 and JNK1, and by upregulation of the epidermal growth factor receptor [17,18]. In experimental autoimmune encephalomyelitis and other demyelinating models, Tβ4 treatment increased newly generated CNPase-positive and MBP-positive oligodendrocytes and reduced axonal damage [18,19]. Second, neuroprotection of endogenous repair capacity: Tβ4 protects spinal cord–derived neural stem/progenitor cells from oxidative injury through the TLR4/MyD88 pathway [20]. Third, angiogenesis and vascular remodelling, which target the ischaemic penumbra that characterises the subacute lesion [16]. Fourth, attenuation of the post-injury inflammatory response, with reduced inflammatory infiltration and pro-inflammatory signalling [8,15].

2.3. Preclinical Evidence in SCI

Cheng and colleagues demonstrated that Tβ4 improves functional recovery after rodent SCI through mechanisms spanning neuronal survival, anti-inflammation, wound repair, and angiogenesis [8]. In related central nervous system injury models, early post-injury administration of Tβ4 reduces cortical lesion volume and hippocampal cell loss after traumatic brain injury and improves functional recovery, supporting a genuine neuroprotective–neurorestorative spectrum rather than a model-specific effect [21,22]. The consistent picture across SCI, demyelinating, and traumatic brain injury models is that Tβ4 acts on remyelination of spared tissue and on the vascular and inflammatory environment in which that tissue sits.

2.4. Human Exposure Data

Human experience with Tβ4 comes almost entirely from topical ophthalmic administration. A randomised, double-masked, placebo-controlled phase II study of 0.1% Tβ4 ophthalmic solution (RGN-259) in 72 subjects with dry eye reported no significant adverse effects, and significant improvements in several secondary signs and symptoms [23]. A subsequent trial in neurotrophic keratopathy showed a strong efficacy trend toward complete corneal healing, again without significant adverse effects [24,25]. These studies establish a limited topical safety record; they provide no information about systemic exposure at regenerative doses, pharmacokinetics after subcutaneous administration, or central nervous system effects in humans. No completed phase 2 or phase 3 trial of Tβ4 exists for SCI, stroke, or traumatic brain injury.

3. BPC-157

3.1. Molecular Pharmacology

BPC-157 is a synthetic, stable pentadecapeptide (GEPPPGKPADDAPGVK) originally derived from a sequence found in human gastric juice, which remains stable and pharmacologically active in gastric juice and in vivo [26,27]. Its lead mechanism is pro-angiogenic cytoprotection: BPC-157 upregulates VEGFR2 expression and promotes receptor internalisation, activating downstream signalling without necessarily raising VEGF ligand levels, and converges on nitric-oxide production through the Akt–eNOS axis [27,28]. Transcriptomic work in injured rats shows upregulation of Egr1, Akt1, Src, Vegfr2, Nos1, and Nos3, with downregulation of Nos2 and Nfkb—a pattern consistent with coordinated pro-repair vascular and anti-inflammatory programming [29].

3.2. Neurorestorative and Cytoprotective Effects

The Croatian literature has established BPC-157’s neural relevance across several preparations: protection of somatosensory neurons, acceleration of peripheral-nerve regeneration after transection and crush, counteraction of the progressive course of traumatic brain injury, and modulation of dopaminergic and serotonergic systems [26,27,28]. The brain–gut axis review by Sikirić and colleagues consolidates these findings and positions BPC-157 as a broadly cytoprotive agent whose effects on endothelial NO signalling may be upstream of many of its tissue-level effects [27].

3.3. Preclinical Evidence in SCI

Two dedicated SCI studies provide the core evidence. Perović et al. (2019) induced a 60-second compression injury of the rat sacrocaudal spinal cord and administered BPC-157 intraperitoneally at 2 µg/kg or 200 µg/kg. All BPC-157–treated animals exhibited consistent clinical improvement, increasingly better tail motor function, absence of autotomy, and resolution of spasticity by day 15, with follow-up extending to one year [9]. The 2022 companion study extended these findings to both definitive and early SCI, reporting recovery after a single administration given ten minutes post-injury [10]. The improvement in both the healing course and functional recovery was dose-consistent and sustained. It must be stated plainly that both studies are rodent, single-centre, and unblinded; they establish biological plausibility, not clinical efficacy.

3.4. Human Exposure Data

Human data for BPC-157 are extremely limited. A narrative review identified only three published human studies: a small retrospective series of intra-articular knee injections (used alone and with material described as TB4), a study in interstitial cystitis, and a pilot pharmacokinetic and safety study of intravenous infusion in two healthy adults, in which doses up to 20 mg were well tolerated with no adverse events or clinically meaningful changes in vital signs, electrocardiograms, or laboratory biomarkers [29,30,31]. The systematic musculoskeletal literature finds only one clinical study among 36 included studies—the evidence base is almost entirely preclinical [32].

4. TB-500 and the Identity Problem

A recurring source of confusion in both the literature and the unregulated market is the conflation of TB-500 with full-length Tβ4. TB-500 is a synthetic, N-acetylated seven-amino-acid fragment (Ac-LKKTETQ, residues 17–23 of Tβ4, approximately 889 Da) matching the actin-binding region of the native 43-amino-acid protein (approximately 4963 Da) [33,34]. Products sold as TB-500 vary, with some labelled as the fragment and others as the full-length molecule. Evidence obtained with one entity cannot be assumed for the other: the fragment lacks the sequences underlying several of the parent molecule’s interactions, and no trial has formally compared them [33,34]. Reviews of unregulated injectable peptide use flag TB-500 and BPC-157 as frequently co-administered in fitness settings without human safety or efficacy trials [34]. Any clinical programme in SCI must therefore specify peptide identity, sequence, purity, and characterisation explicitly, distinguishing full-length Tβ4 from TB-500 at every step.

5. Rationale for Combining Tβ4 and BPC-157 in SCI

The two peptides are mechanistically non-redundant, and their combination plausibly addresses the principal repair requirements of the subacute cord simultaneously, as summarised in Table 1.
In short, BPC-157 may restore the vascular substrate while Tβ4 acts on the cytoskeletal and glial machinery of regrowth, with rehabilitation supplying the activity-dependent signal that determines where new connectivity is consolidated. The timing of administration relative to training sessions may matter: pairing drug exposure with periods of peak activity-dependent signalling is a rational, though untested, scheduling principle [11].

6. First Clinical Evidence in Human SCI

6.1. The AIS-B Thoracic Pilot Study

The first human study of either peptide in SCI—and the first of the combination in any indication—was reported by Majumdar and colleagues in 2026 [11]. Ten adults (aged 21–39 years) with traumatic thoracic SCI graded AIS B, 6–8 months post-injury, were enrolled into two level-matched groups of five. The peptide group received weekly subcutaneous Tβ4 1.65 mg and BPC-157 0.8 mg for 26 consecutive weeks (cumulative 42.9 mg and 20.8 mg, respectively), and both groups completed identical intensive rehabilitation (2 hours per day, 5 days per week). The primary outcome was change in Lower Extremity Motor Score (LEMS, maximum 50 points).
All ten participants completed 26 weeks, with 100% injection adherence and retention. Mean LEMS at six months reached 29.4 ± 3.8 points (58.8% of the 50-point maximum) in the peptide group versus 19.0 ± 3.5 points (38.0%) in the rehabilitation-only group—an absolute difference of 10.4 points, with complete stochastic dominance between the arms exact two-sided p = 0.008, Cliff’s δ = 1.00). Light-touch and pin-prick totals rose by 22.2 and 19.8 points versus 11.4 and 9.8 in the comparator; motor zone of partial preservation descended a median of two levels versus one; trunk-control scores and bladder–bowel measures improved roughly twice as much as with rehabilitation alone; and two peptide-group participants achieved voluntary knee locking and assisted overground ambulation, versus none in the comparator arm [11].
No serious adverse events occurred. Reported effects were mild and transient: injection-site erythema or itch (3 participants), injection-site induration (2), transient post-injection lightheadedness (2), transient headache (1), and one asymptomatic ALT rise to 1.6 × the upper limit of normal that normalised without dose change [11].
The investigators themselves characterised these findings as hypothesis-generating. The study was small (five per arm), open-label, non-randomised, and unblinded, with no placebo injection in the comparator arm, and recovery magnitudes in both arms exceeded published natural-history and locomotor-training benchmarks. As the authors noted, the absolute values should therefore carry limited weight; the relative between-arm separation is the signal that merits confirmatory testing [11]. A particularly interesting feature was the temporal shape of the divergence: the between-group LEMS gap widened progressively at every assessment (1.2 to 4.0 to 6.8 to 9.0 to 10.4 points), a pattern more compatible with a slow structural process—angiogenic maturation and remyelination of a spared rim—than with a front-loaded expectancy effect [11].

6.2. Emerging Combination Protocols

A subsequent investigator-initiated study has extended peptide-based protocols to complete (AIS A) SCI: a single-centre, randomised, double-blind, placebo-controlled trial of an NVG-291-designated peptide combined with TB-4, reported as a preprint, in which the combination arm showed greater improvement in lower-limb motor scores, standing endurance, and walker-supported walking than placebo over 12 months, with no documented adverse events [35]. As a preprint, these findings await peer review, but they signal a shift of peptide protocols in SCI from open-label pilot designs toward blinded, randomised evaluation—the direction the field requires.

7. Safety, Pharmacokinetics, and Regulatory Considerations

Neither Tβ4 nor BPC-157 is an approved medicinal product for SCI, or for any systemic indication, in any major jurisdiction. Three regulatory facts frame any clinical use. First, the US FDA has placed BPC-157 on its list of bulk drug substances that may present significant safety risks in compounding, citing immunogenicity risk for certain routes of administration and peptide-characterisation complexities, and FDA’s own review identified essentially no adequate clinical studies in relevant populations [36,37]. Second, both peptides fall within category S0 (non-approved substances) of the WADA Prohibited List, prohibited at all times in sport [38]. Third, the products circulating in unregulated markets are of variable identity, purity, and sterility, and the TB-500/full-length Tβ4 conflation described above compounds the risk [33,34].
Specific evidence gaps deserve emphasis. Anti-drug antibody titres were not measured in the AIS-B pilot, a notable omission given the FDA’s specific immunogenicity concern for compounded BPC-157 [11,36]. Pharmacokinetics after subcutaneous administration at regenerative doses have not been characterised for either peptide; the pilot’s Tβ4 dose (approximately 0.024 mg/kg weekly for a 70 kg adult) is roughly two orders of magnitude below typical rodent per-dose exposures, whereas its BPC-157 dose (approximately 11 µg/kg weekly) is of comparable magnitude to rodent per-dose amounts on a body-weight basis, administered far less frequently [11]. Whether signalling effects outlast plasma presence—a plausible property of agents that act through receptor upregulation and transcriptional programmes—is untested in humans. Finally, theoretical concerns about pro-angiogenic peptides and occult neoplasia cannot be addressed by a 6-month study in five people and require long-term safety registries in any successor programme [11].

8. Limitations of the Evidence and Requirements for a Confirmatory Trial

The current evidence base is preclinical-first, small, and uncontrolled at the clinical level. The principal limitations are: (i) rodent-only efficacy data for BPC-157 in SCI; (ii) no randomised, blinded, placebo-controlled trial of either peptide in SCI; (iii) the open-label, unblinded design of the AIS-B pilot, in which examiner expectation and differential effort cannot be excluded; (iv) absence of examiner-independent objective corroboration (MRI, motor and somatosensory evoked potentials, electromyography) in the human data; and (v) uncharacterised pharmacokinetics, dose–response, and long-term safety.
Table 2 summarises the design elements that the collective evidence suggests for a confirmatory trial.

9. Conclusions

Tβ4 and BPC-157 are mechanistically complementary regenerative peptides whose preclinical profiles map closely onto the pathological requirements of the subacute spinal cord: perfusion, remyelination of a spared rim, progenitor survival, and inflammatory control. Human exposure data are limited but not alarming, and the first clinical study in SCI—a 6-month open-label controlled pilot of the combination in AIS B thoracic injury—reported substantially larger motor, sensory, trunk, and autonomic gains than matched rehabilitation alone, with only mild and transient adverse effects [11]. That study is best read as a strong hypothesis-generating signal with an internally coherent temporal and anatomical pattern, not as evidence of efficacy. The path forward is clearly marked: a properly powered, randomised, double-blind, placebo-controlled factorial trial with blinded neurophysiological endpoints, pharmacokinetic and immunogenicity sub-studies, and long-term safety follow-up. Until such data exist, neither peptide should be used for SCI outside a regulated, ethically approved, and adequately monitored trial.

Author Contributions

Conceptualisation, P.M.; writing—original draft preparation, P.M.; writing—review and editing, S.K., U.J., G.M., M.A. and I.L. All authors have read and agreed to the published version of the manuscript.

Funding

This research received no external funding.

Conflicts of Interest

The authors declare no conflict of interest.

References

  1. Kirshblum, S.; Snider, B.; Rupp, J.; Read, M.S. (Eds.) International Standards for Neurological Classification of Spinal Cord Injury, revised 2019. Top. Spinal Cord Inj. Rehabil. 2019, 25 (Suppl. 1), S1–S224.
  2. ASIA/ISCOS. International Standards for Neurological Classification of Spinal Cord Injury (ISNCSCI) Worksheet, 2019. Available online: https://asia-spinalinjury.org/wp-content/uploads/2019/04/ASIA-ISCOS-IntlWorksheet_2019.pdf (accessed on 13 November 2026).
  3. Fawcett, J.W.; Curt, A.; Steeves, J.D.; et al. Guidelines for the conduct of clinical trials for spinal cord injury as developed by the ICCP panel: Spontaneous recovery after spinal cord injury and statistical power needed for therapeutic clinical trials. Spinal Cord. 2007, 45, 190–205. [Google Scholar] [CrossRef] [PubMed]
  4. Wilson, J.R.; Cadotte, D.W.; Fehlings, M.G. Clinical predictors of neurological outcome, functional status, and survival after traumatic spinal cord injury: A systematic review. J. Neurosurg. Spine 2012, 17, 11–26. [Google Scholar] [CrossRef] [PubMed]
  5. Ahmed, U.; et al. Characterising natural recovery after traumatic spinal cord injury. Available online: https://pmc.ncbi.nlm.nih.gov/articles/PMC8080912/ (accessed on 13 November 2026).
  6. Behrman, A.L.; Harkema, S.J. Locomotor training after human spinal cord injury: A series of case studies. Phys. Ther. 2000, 80, 688–700. [Google Scholar] [CrossRef]
  7. Kunming Locomotor Training: Neurological, functional, and autonomic outcomes. Available online: https://pmc.ncbi.nlm.nih.gov/articles/PMC12594139/ (accessed on 13 November 2026).
  8. Cheng, P.; Kuang, J.; Zhu, H.; et al. Beneficial effects of thymosin β4 on spinal cord injury in the rat. Neurosci. Lett. 2014, 570, 74–79. [Google Scholar]
  9. Perović, D.; Kolenc, D.; Bilić, V.; et al. Stable gastric pentadecapeptide BPC 157 can improve the healing course of spinal cord injury and lead to functional recovery in rats. J. Orthop. Surg. Res. 2019, 14, 199. [Google Scholar] [CrossRef] [PubMed]
  10. Novel therapeutic effects in rat spinal cord injuries: Recovery of the definitive and early spinal cord injury by the administration of pentadecapeptide BPC 157 therapy. Available online: https://pmc.ncbi.nlm.nih.gov/articles/PMC9164058/ (accessed on 13 November 2026).
  11. Majumdar, P.; Kaura, S.; Jafarova, U.; Matis, G.; Alam, M.; Rodriguez, A. Adjunctive weekly subcutaneous thymosin β4 and BPC-157 with intensive rehabilitation in subacute AIS-B thoracic spinal cord injury: A 6-month open-label controlled pilot study. Am. J. Med. Clin. Res. Rev. 2026, 5, 1–21. [Google Scholar] [CrossRef]
  12. Irobi, J.; Agten, A.; Linders, J.T.; et al. Structural basis of actin sequestration by thymosin-β4: Implications for actin dynamics. EMBO J. 2003, 22, 3559–3568. [Google Scholar] [CrossRef] [PubMed]
  13. Goldstein, A.L.; Hannappel, E.; Sosne, G.; Kleinman, H.K. Thymosin β4: Actin-sequestering protein moonlights to repair injured tissues. Trends Mol. Med. 2005, 11, 421–429. [Google Scholar] [CrossRef] [PubMed]
  14. Thymosin β4 promotes zebrafish Mauthner axon regeneration by facilitating actin polymerization through binding to G-actin. Available online: https://pmc.ncbi.nlm.nih.gov/articles/PMC11515629/ (accessed on 13 November 2026).
  15. Sosne, G.; Qiu, P.; Goldstein, A.L.; Wheater, M. Biological activities of thymosin β4 defined by active sites in short peptides. Peptides 2010, 31, 1018–1023. [Google Scholar]
  16. Sosne, G.; Morrison, A.L. Thymosin β4 as a restorative/regenerative therapy for neurological injury and neurodegenerative diseases. Expert Opin. Biol. Ther. 2015, 15, 185–192. [Google Scholar] [CrossRef] [PubMed]
  17. Chew, L.J.; Zhou, X.; Zhang, Y.; et al. Thymosin beta 4 mediates oligodendrocyte differentiation by upregulating p38 MAPK. Glia 2013, 61, 1169–1182. [Google Scholar] [CrossRef] [PubMed]
  18. Thymosin beta 4 promotes oligodendrogenesis in the demyelinating central nervous system. Neurobiol. Dis. 2016, 86, 73–86. [CrossRef] [PubMed]
  19. Sanchez, S.; Bhatt, K.; Berman, N.E.; et al. A dose response study of thymosin β4 for the treatment of an animal model of multiple sclerosis. Available online: https://pmc.ncbi.nlm.nih.gov/articles/PMC4177939/ (accessed on 13 November 2026).
  20. Zhu, J.; et al. Thymosin beta 4 attenuates oxidative stress-induced injury of spinal cord-derived neural stem/progenitor cells through the TLR4/MyD88 pathway. Gene 2019, 704, 81–87. [Google Scholar] [CrossRef] [PubMed]
  21. Xiong, Y.; Mahmood, A.; Meng, Y.; et al. Neuroprotective and neurorestorative effects of thymosin β4 treatment following experimental traumatic brain injury. Ann. N. Y. Acad. Sci. 2012, 1270, 51–58. [Google Scholar] [CrossRef] [PubMed]
  22. Xiong, Y.; Zhang, Y.; Mahmood, A.; Meng, Y.; Chopp, M. Neuroprotective and neurorestorative effects of thymosin β4 following experimental traumatic brain injury. Available online: https://pmc.ncbi.nlm.nih.gov/articles/PMC3547647/ (accessed on 13 November 2026).
  23. Sosne, G.; Chan, C.C.; Thompson, D.; et al. Thymosin β4 ophthalmic solution for dry eye: A randomized, placebo-controlled, double-masked clinical trial. Available online: https://pmc.ncbi.nlm.nih.gov/articles/PMC4445951/ (accessed on 13 November 2026).
  24. Dunn, A.L.; Heid, D.G.; Chicani, P.J.; et al. 0.1% RGN-259 (thymosin β4) ophthalmic solution improves signs and symptoms of neurotrophic keratopathy. Int. J. Mol. Sci. 2023, 24, 554. [Google Scholar]
  25. RGN-259 (thymosin β4) improves clinically important dry eye signs and symptoms. Sci. Rep. 2018, 8, 12595. [CrossRef] [PubMed]
  26. Sikirić, P.; Seiwerth, S.; Rucman, R.; et al. Brain-gut axis and pentadecapeptide BPC 157: Theoretical and practical implications. Curr. Neuropharmacol. 2016, 14, 857–865. [Google Scholar] [CrossRef] [PubMed]
  27. Sikirić, P.; Seiwerth, S.; Rucman, R.; et al. Toxicity by NSAIDs and increased survival with BPC 157: Insights from the brain-gut axis and pentadecapeptide BPC 157. Available online: https://pmc.ncbi.nlm.nih.gov/articles/PMC5333585/ (accessed on 13 November 2026).
  28. Vukojević, J.; Siroglavić, M.; Kažar, T.; et al. Pentadecapeptide BPC 157 and the central nervous system. Neural Regen. Res. 2022, 17, 470–475. [Google Scholar] [CrossRef] [PubMed]
  29. Regeneration or risk? A narrative review of BPC-157. Sports Med. Arthrosc. Rehabil. Sci. Technol. 2025. Available online: https://pmc.ncbi.nlm.nih.gov/articles/PMC12446177/ (accessed on 13 November 2026).
  30. Lee, E.; Padgett, B. Intra-articular knee pain injection with BPC 157: A retrospective case series. 2021. [Google Scholar] [PubMed]
  31. Lee, E.; Burgess, K. Safety of intravenous infusion of BPC157 in humans: A pilot study. Altern. Ther. Health Med. 2025. [Google Scholar] [CrossRef] [PubMed]
  32. Investigational peptides in orthopaedic practice: Evidence, safety, and patient counselling for BPC-157, thymosin beta-4, and TB-500. 2026. [PubMed]
  33. Dangers of injectable peptides and other unregulated ‘biohacking’ drugs. 2025. Available online: https://pmc.ncbi.nlm.nih.gov/articles/PMC13585006/ (accessed on 13 November 2026).
  34. TB-500 vs thymosin beta-4: A synthetic 7-amino-acid fragment (Ac-LKKTETQ) distinct from the full-length 43-amino-acid protein. Available online: https://usa.alphagenics.co/blog/tb-500-no-es-timosina-beta-4/ (accessed on 13 November 2026).
  35. Majumdar, P.; Lavrov, I.; Ahemad, N.; Ismayilzada, R.; Alam, M.; Matis, G.; Fenoy, A.J.; Jafarova, U. Investigational study of an NVG-291-designated peptide with thymosin beta-4 (TB-4) in complete spinal cord injury: Clinical outcomes over a 12-month follow-up. Preprints 2026, 2026111027. [Google Scholar] [CrossRef]
  36. U.S. Food and Drug Administration. Certain bulk drug substances for use in compounding that may present significant safety risks. Available online: https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks (accessed on 13 November 2026).
  37. U.S. Food and Drug Administration. Pharmacy Compounding Advisory Committee briefing document: BPC-157. Available online: https://www.fda.gov/media/193343/download (accessed on 13 November 2026).
  38. World Anti-Doping Agency. The 2026 Prohibited List (S0: non-approved substances). Available online: https://www.wada-ama.org/sites/default/files/2025-09/2026list_en_final_clean_september_2025.pdf (accessed on 13 November 2026).
Table 1. Complementary repair-relevant contributions of Tβ4 and BPC-157 after SCI.
Table 1. Complementary repair-relevant contributions of Tβ4 and BPC-157 after SCI.
Repair requirement after SCI Tβ4 contribution BPC-157 contribution
Perilesional perfusion Neurovascular remodelling VEGFR2-driven angiogenesis; Akt–eNOS NO release
Axonal growth-cone motility G-actin sequestration; filament severing/capping Neuromuscular stabilisation; nerve-regeneration signalling
Inflammatory tone Reduced inflammatory infiltration Cytoprotection; oxidative-stress buffering; Nfkb downregulation
Endogenous progenitor survival NSPC protection via TLR4/MyD88 Fibroblast/stromal signalling; tissue integrity
Remyelination Oligodendrogenesis via p38 MAPK and EGFR Indirect, via improved perfusion
Table 2. Suggested design elements for a confirmatory trial of Tβ4 + BPC-157 in SCI.
Table 2. Suggested design elements for a confirmatory trial of Tβ4 + BPC-157 in SCI.
Element Specification
Design Randomised, double-blind, placebo-controlled; 2 × 2 factorial (Tβ4 ± BPC-157) to resolve individual contributions
Control Matching subcutaneous placebo of identical volume, appearance, and schedule; identical rehabilitation dose
Blinding Participants, therapists, and two independent ISNCSCI examiners blinded to allocation and prior scores
Sample size ≥ 30 per arm, powered on a 6-point LEMS between-group difference (SD 6, α 0.05, power 0.80, ~20% attrition)
Stratification Neurological level (T1–T6 / T7–T12) and post-injury interval
Primary outcome LEMS change at 26 weeks with blinded assessment
Key secondary WISCI-II; TCT-SCI; ISNCSCI sensory totals; NBD score; urodynamics; AIS conversion
Objective corroboration Serial MRI with diffusion metrics; motor and somatosensory evoked potentials; surface EMG of key myotomes
Sub-studies Pharmacokinetics of both peptides; anti-drug antibody titres; VEGF, GFAP, NfL, NSE panels
Dose exploration Dose-ranging arm, given the two-log gap between this regimen and preclinical Tβ4 exposures
Follow-up ≥ 52 weeks, with a 5-year safety registry given the pro-angiogenic mechanism
Governance Multicentre; independent DSMB; central ISNCSCI adjudication; prospective registration with a published statistical analysis plan
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.
Copyright: This open access article is published under a Creative Commons CC BY 4.0 license, which permit the free download, distribution, and reuse, provided that the author and preprint are cited in any reuse.